Figure 1 Platelet receptors and available pharmaceutical options

Slides:

Advertisements

Similar presentations

Novel antithrombotic agents in acute coronary syndromes: better or worse than P2Y12 inhibitors Giuseppe Biondi Zoccai Sapienza Università di Roma

Advertisements

Platelet thrombin receptor antagonism and atherothrombosis by Dominick J. Angiolillo, Davide Capodanno, and Shinya Goto EHJ Volume 31(1):17-28 January.

II. Antiplatelet Drugs.

A. Mechanism of action of aspirin

Nat. Rev. Cardiol. doi: /nrcardio

Aspirin and Clopidogrel Resistance

Figure 2 Electromechanical properties of OIHPs

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Metabolism pathway of antiplatelet agents

Figure 2 Binding properties of P2Y12-receptor inhibitors

Mandeep Singh, MD, MPH, Deepak L. Bhatt, MD, MPH, Gregg W

Figure 1 Newly discovered mechanistic pathways

Nat. Rev. Cardiol. doi: /nrcardio

Figure 8 Implanted devices for the management of heart failure

Figure 4 Pharmacodynamic comparison of crushed versus integral

Figure 4 BMI and mortality in patients with heart failure

Figure 1 Old age, metabolites, and chronic inflammation

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Global rates of sodium, fruit, and vegetable intake

Figure 1 Mechanism of thrombus formation during ST-segment

Figure 1 Anatomy of the femoral artery

Figure 1 Antiplatelet and anticoagulant pathways

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Three-year survival rates on the basis of body composition

Aspirin and Clopidogrel Resistance

Nat. Rev. Cardiol. doi: /nrcardio

ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 Pharmacodynamic profile of switching between clopidogrel and ticagrelor therapy: results from the RESPOND study Figure 6| Pharmacodynamic profile.

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Health-care system today

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Cardiovascular risk and disease across the life-course

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Decision tree integrating the assessment,

Figure 3 Neural crest cell migration

Figure 2 Global cost of HF per capita in 2012

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Challenges for big data applications in cardiovascular care

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 5 Bioresorbable vascular scaffold apposition and strut coverage

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 The neurogenic components of angina

MicroRNAs in Memory Processing

Figure 1 Mechanisms of platelet adhesion and aggregation

Nat. Rev. Cardiol. doi: /nrcardio

Volume 81, Issue 12, Pages (June 2012)

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Electrocardiogram patterns associated with Brugada syndrome

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Impaired mitochondrial capacity and function in heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 4D printing schemes and time-evolving structure geometries

Figure 3 Adverse cardiovascular consequences of synthetic cannabinoids

Figure 3. Trials and possible strategies for un-guided and guided DAPT de-escalation. The figure shows studies and strategies on DAPT de-escalation approaches.

Overview of important signalling pathways in angiogenesis and antiangiogenic agents. Overview of important signalling pathways in angiogenesis and antiangiogenic.

Platelet activation pathways and sites targeted by current and novel antiplatelet agents. Platelet activation pathways and sites targeted by current and.

Presentation transcript:

Figure 1 Platelet receptors and available pharmaceutical options Figure 1 | Platelet receptors and available pharmaceutical options. Current and emerging antiplatelet therapies are based on blockade of the thromboxane pathway, inhibition of platelet activation, and serotonin receptor 2A antagonism. 5-HT2A, serotonin receptor 2A; COX, cyclooxygenase; GP, glycoprotein; PAR, protease-activated receptor; TP, thromboxane prostanoid receptor; TXS, thromboxane A2 synthase; vWF, von Willebrand factor. Reprinted from Franchi, F. et al. Novel antiplatelet agents in acute coronary syndrome. Nat. Rev. Cardiol. 12 (10), 30–47 (2015), with permission from Macmillan Publishers Limited. Reprinted from Franchi, F. et al. Novel antiplatelet agents in acute coronary syndrome. Nat. Rev. Cardiol. 12 (10), 30–47 (2015), with permission from Macmillan Publishers Limited Serebruany, V. & Golukhova, E. (2017) Aspirin in the elderly — tailored approaches ahead? Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.117